Skip to content
ClinCalc Pro
Menu
Anti-obesity (combination)

Naltrexone with bupropion

Brand names: Mysimba

A modified-release oral combination of the opioid antagonist naltrexone and the antidepressant/smoking-cessation agent bupropion, used as an adjunct to diet and exercise for weight management in adults with obesity or overweight with comorbidities.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

The two agents act centrally on appetite-regulating pathways, with bupropion stimulating hypothalamic neurones and naltrexone blocking an opioid-mediated feedback loop, together reducing appetite and food intake.

Prescribing in practice

  • Because bupropion lowers the seizure threshold, the combination is contraindicated in epilepsy or conditions predisposing to seizures, and must not be used with opioids or in opioid dependence owing to the naltrexone component.
  • It is contraindicated with monoamine oxidase inhibitors and in uncontrolled hypertension, and can raise blood pressure and heart rate.
  • Review for adequate weight loss after an initial period and discontinue if the response is insufficient, while monitoring mood given bupropion's psychiatric effects.

Monitoring

Monitor blood pressure and heart rate, weight response, and mood or behavioural changes including any suicidal ideation.

Counselling the patient

  • Swallow the tablets whole with the dose built up gradually, and do not take with a high-fat meal.
  • Do not take any opioid painkillers while on this medicine and tell healthcare staff you take it before any procedure.
  • Report low mood, agitation or thoughts of self-harm.

Evidence & guidelines

Naltrexone-bupropion is licensed for weight management as an adjunct to lifestyle measures, with trials showing modest additional weight loss; NICE has appraised its place in therapy.

Reference: NICE TA494; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.